Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of Temozolomide in Combination With Targeted Therapy for NSCLC Patients With CNS Progression on Either Osimertinib or Lorlatinib

NCT04541407 is registered in ClinicalTrials.gov with University of Colorado, Denver as lead sponsor.

NCT NCT04541407
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04541407 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of Temozolomide in Combination With Targeted Therapy for NSCLC Patients With CNS Progression on Either Osimertinib or Lorlatinib
Lead sponsor
University of Colorado, Denver
Phase
Phase 1
Overall status
Completed
Start date
October 29, 2020
Completion date
June 7, 2022
Enrollment
1 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cns progression, non small cell lung cancer